Drug Type Antibody fusion proteins |
Synonyms |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), Protease inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 1 | GB | 04 Aug 2021 |